| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fbcdb105756f552ddf2e9ae2cfcf40a |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-121 |
| filingDate |
2004-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_723d7a74718d8488357c32561ba25874
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ff77b8f7b204357c2d0f4ca91326053 |
| publicationDate |
2006-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2006063012-A |
| titleOfInvention |
Anti-polyglutamine disease agent |
| abstract |
PROBLEM TO BE SOLVED: To provide a novel drug (medicine) for polyglutamine disease. An anti-polyglutamine disease agent is composed of geranylgeranylacetone (GGA) represented by the following formula as an active ingredient. Polyglutamine disease is an inherited neurodegenerative disease and includes bulbospinal muscular atrophy, Huntington's disease and spinocerebellar degeneration. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9119808-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-5483513-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014185139-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9045403-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008038712-A1 |
| priorityDate |
2004-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |